随着该公司的股票价格升至0.88美元,Spero治疗公司首席执行官和首席财务干事出售了大量股份。 Spero Therapeutics' CEO and CFO sold significant shares as the company’s stock price rose to $0.88.

2月5日,Sath Shukla CFO Esther Rajavelu和CEO Sath Shukla出售了大量公司股份,分别减少了2.78%和8.21%的所有权。 Spero Therapeutics CFO Esther Rajavelu and CEO Sath Shukla sold a significant number of company shares on February 5th, reducing their ownership by 2.78% and 8.21% respectively. 那一天,SPRO的股票价格上涨到0.88美元。 SPRO's stock price increased to $0.88 on that day. 该公司着重于发展细菌感染和罕见疾病的治疗,市场上限为4 781万美元,PE比率为12.53。 The company, focusing on developing treatments for bacterial infections and rare diseases, has a market cap of $47.81 million and a PE ratio of 12.53. 尽管内部股票销售情况良好,分析人员仍对SPRO保持积极的评级。 Despite internal stock sales, analysts have maintained positive ratings on SPRO.